Control peptide for C1385-40 (antiserum) and C1385-45 (affinity purified antibody). Synthetic peptide consisting of 13aa sequence mapping near the C-terminus of mouse CPT1-M. No significant sequence homology is seen with LCPT-1, CPT-2 or any other protein. Species crossreactivity: Rat: 92%; human: 69%.
In cells and organisms, the excess of metabolic fuel is converted into fatty acids in cytosol and oxidized later in mitochondria to generate ATP and acetyl-CoA. In fatty acid synthesis, catalytic formation of malonyl-CoA (precursor for long-chain fatty acyl-CoA, LCFA-CoA) from acetyl-CoA by Acetyl-CoA carboxylase (ACC-1). Activities of ACC-1 and ACC-2 are regulated by their phosphorylation by 5'-AMP-activated protein kinase (AMPK). Diabetes deranges AMPK master-switch, represses the ACC-1 gene-expression and stimulates excessive fatty acid oxidation which in turn interferes with glucose metabolism. Cytosolic LCFA-CoA is converted into acyl-carnitine at mitochondrial membrane surface by carnitine palmitoyl transferase-1 (CPT-1) followed by the reconversion of the latter into LCFA-CoA by CPT-2 in the mitochondrial matrix. Mitochondrial oxidation of LC-FCA is initiated by the sequential action of CPT-1, which is located in the outer membrane, and CPT-2, which is located in the inner membrane together with a carnitine-acylcarnitine translocase. CPT-1 liver or CPT1A or LCPT-1 (mouse 764aa, rat 773aa, human 773aa, ~88kD, chromosome 11q13) is malonyl-CoA-sensitive enzyme localized on the outer surface of mitochondrial 'contact sites'. It catalyzes the conversion of long-chain acyl-CoA into acyl-carnitine, committing the acyl moiety to intramitochondrial oxidation. It is predominantly expressed in kidney, liver and in trace amounts in heart. The 'muscle' isoform CPT1B or CPT1M or MCPT-1 (mouse/rat/human 772aa, chromosome 22q13.3) is found in heart, skeletal muscle, adipose tissue and brain. The aa sequences of the two isoforms are ~61% identical.
Applications:Suitable for use in ELISA and Antibody Blocking. Not suitable for use in Western Blot due to low molecular weight. Other applications not tested.
Recommended Dilution:ELISA: 50-100ng of control peptide/well
Antibody Blocking: 5-10ug per 1ul C1385-40 (antiserum) or per 1ugC1385-45 (affinity purified antibody)
Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only. For long-term storage, store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
